Search Results 831-840 of 17414 for alopecia

  1. Study of TJ011133 in Participants With Relapsed/ Refractory Advanced Solid Tumors and Lymphoma - Mayo Clinic

    Not recovered (i.e., to ≤ Grade 1 or to baseline) from AEs emerging from previous treatments (except alopecia or neuropathy). Incomplete recovery from AEs ...

  2. A Study to Evaluate HKI-272 and Capecitabine for HER2-Positive Breast Cancer and Brain Metastases - Mayo Clinic

    ... alopecia). Washout from trastuzumab or hormonal therapy is not required. Participants who are currently receiving any other investigational agents. History ...

  3. Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination with Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer - Mayo Clinic

    ... alopecia;; Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs. If clarification is ...

  4. Mayo Clinic

    ... . IMG-20457598. Home; cc-mobile-stem-cell-research_mobile. Double your impact on cancer! Give Now. Make a gift before July 31 and it can be doubled in ...

  5. Nutrition and healthy eating Healthy diets - Mayo Clinic

    You can master healthy eating by learning how to plan meals and shop smart, and by practicing healthy-cooking techniques.

  6. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effectiveness of AMG 397 in Subjects With Multiple Myeloma, NHL, and AML - Mayo Clinic

    ... alopecia or toxicities from prior anti-tumor therapy that are considered irreversible (defined as having been present and stable for > 4 weeks prior to ...

  7. Audiology - Conditions treated - Mayo Clinic

    Mayo Clinic ear, nose and throat (ENT)/head and neck specialists treat medical conditions that cause hearing loss, dizziness or imbalance and offer a full range ...

  8. A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Impaired Renal Function - Mayo Clinic

    Any unresolved toxicity ≥ Grade 2 from previous treatment except for alopecia, or peripheral neuropathy up to Grade 2. Plasmapheresis within 7 days prior ...

  9. Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas - Mayo Clinic

    Patients who have not recovered to Grade 1 or baseline from adverse events related to prior therapy excluding lymphopenia, alopecia, peripheral neuropathy ...

  10. A Study to Evaluate Tazemetostat and Pembrolizumab to Treat Advanced Urothelial Carcinoma - Mayo Clinic

    Note: patients with ≤ grade 2 neuropathy or ≤ grade 2 alopecia or ≤ grade 3 audiometric hearing loss are an exception to this criterion and may qualify for ...